Time filter

Source Type

Zhao J.,Sichuan Provincial Cancer Hospital | Li L.,Sichuan Provincial Cancer Hospital | Peng L.,Sichuan Provincial Cancer Hospital
International Journal of Clinical and Experimental Pathology

The previous studies identify mammalian heart is terminal differentiation organs without regenerative capacity. Recently, there is some evidence point that cardiomyocytes are not terminally differentiated cells and cell proliferation may be stimulated in the pathologic heart. The aim of this study is to discover the possible mechanism which involved in cardiomyocytes proliferation process. In this study, the proliferation assay and cell cycle assay showed the proliferation of cardiomyocytes was inhibited when the cells treated with MAPK1 inhibitor. Moreover, the bioinformatics analysis revealed MAPK1 was positively correlated with MALAT1. Meanwhile, the expression of MALAT1 in H9C2 cells with the treatment of MAPK1 siRNA was obvious lower than scramble siRNA treated group. Finally further study suggested H9C2 cells treated with Wortmannin in combination with LY294002 (PI3K/AKT signaling pathway inhibitor), the expression of MALAT1 was dramatically decreased. These results indicated that MAPK1 was able to increase the proliferation of cardiomyocytes via up-regulating the expression of MALAT1 through PI3K/AKT signaling pathway. Source

Jiang Q.,Sichuan Provincial Cancer Hospital | Jiang G.,Sichuan Provincial Cancer Hospital | Wang Y.-X.,Sichuan Provincial Cancer Hospital
Chinese Journal of Cancer Prevention and Treatment

OBJECTIVE: To evaluate correlation between ERCC1 expression and efficacy of platinum-based chemotherapy in non-small cell lung cancer patients according to evidence-based medicine view, and provide evidence about individual treatment. METHODS: Chinese and English database was searched on cut-off Feb 2011, and controlled study about correlation among ERCC1 expression and efficacy of platinum-based chemotherapy in Chinese patients with non-small cell lung cancer were included. Meta-analysis was conducted by the RevMan 4.2.8 software. RESULTS: Seventeen studies with 1 293 patients were identified, including 611 patients with ERCC1 positive expression and 682 with ERCC1 negative expression. There was no significantly statistical heterogeneity (χ 2=11.45, P=0.41); random-effect pooled OR ratio was 2.82, 95%CI was 2.12 to 3.74, and P<0.00001. No bias was detected (P=0.244). CONCLUSIONS: ERCC1 negative expression can predict the curative efficacy of platinum-based chemotherapy. However, there is no sufficient evidence explaining whether it can predict survival time. Source

Zhao J.,Sichuan Provincial Cancer Hospital | Li L.,Sichuan Provincial Cancer Hospital | Peng L.,Sichuan Provincial Cancer Hospital
International Journal of Clinical and Experimental Medicine

The aim of this study was to investigate the clinical outcome of intracardiac echocardiography (ICE) for transcatheter closure of atrial septal defect (ASD) compared with the trans-esophageal echocardiography (TEE) guided method. From May 2010 to April 2011, 46 patients who underwent ICE guided (n = 23) or TEE guided (n = 23) transcatheter closure of ASD were analyzed retrospectively. We compared the demographic characteristic, procedure parameters and outcomes between ICE-and TEE-guided groups. No significant difference was found between 2 groups on demographic characteristics. Fluoroscopy time and procedure time was significantly decreased in ICE guided group than that in TEE-guided group. In addition, no significant difference was found on treatment outcomes, complications between these 2 groups. ICE-guided ASD occlusion is safe and effective method, which provides more accurate anatomical information, shorter fluoroscopy time and procedure time. © 2015, E-Century Publishing Corporation. All rights reserved. Source

Zhang P.,Sichuan Provincial Cancer Hospital | Wu S.-K.,Cangxi Peoples Hospital | Wang Y.,Sichuan Provincial Cancer Hospital | Fan Z.-X.,Sichuan Provincial Cancer Hospital | And 5 more authors.
Oncology Letters

In the present study, the expression of p53, mouse double minute 2 homolog (MDM2), eukaryotic translation initiation factor 4E (eIF4E), and epidermal growth factor receptor (EGFR) were investigated in nasopharyngeal carci­noma (NPC), and the correlation between their expression and clinicopathological characteristics and prognosis was analyzed. The medical records of 96 NPC patients who had undergone biopsy prior to radical radiotherapy and chemotherapy between 2005 and 2009 were reviewed, retrospectively. All patients received intensity-modulated radiotherapy with concurrent platinum-based chemotherapy. Patients were followed-up for three years. Streptavidin-peroxidase immunohistochemistry was used to evaluate the expression of p53, MDM2, eIF4E and EGFR in NPC biopsy specimens, and the association between their expression and clinical parameters and survival was analyzed. The p53, MDM2, eIF4E and EGFR expression rates were 65.6% (63/96), 79.16% (76/96), 77.08% (74/96) and 89.5% (86/96), respectively. p53 (χ2,20.322; P=0.001) and EGFR (χ2,8.337; P=0.005) expression were found to correlate with T stage, whereas MDM2 (χ2,16.361; P=0.001) expression was found to correlate with lymph node metastasis. p53 expression was found to inversely correlate with   MDM2 expression (r, -3.24; P<0.05). Three-year survival rates were lower in p53-positive (76.2%) patients when compared with p53-negative (93.9%) patients. In addition, three-year survival rates were lower in EGFR-positive (75.8%) patients than in EGFR-negative patients (91.2%). The Cox propor­tional-hazards regression model revealed that p53 (β, -0.455; χ2,5.491; P=0.019) and EGFR (β, 3.93; χ2, 11.95; P=0.001) expression were independent prognostic factors. Thus, it was hypothesized that p53 and EGFR expression present potential unfavorable prognostic markers for patients with NPC. © 2015, Spandidos Publications. All rights reserved. Source

Zou B.,Cancer Center | Xu Y.,Cancer Center | Li T.,Sichuan Provincial Cancer Hospital | Li W.,Yunnan Provincial Cancer Hospital | And 14 more authors.
International Journal of Radiation Oncology Biology Physics

Purpose: To retrospectively evaluate the role of postoperative chemoradiotherapy (POCRT) in patients with completely resected non-small-cell lung cancer (NSCLC) with N2 lymph node involvement. Methods and Materials: This study included 183 patients from four centers in southwest China who underwent radical section of Stage III-N2 NSCLC without any preoperative therapy. One hundred and four were treated with POCRT and 79 with postoperative chemotherapy (POCT) alone. The median radiation dose to clinical target volume (CTV) was 50 Gy (varying between 48 and 54 Gy), whereas the cycles of platinum-based chemotherapy ranged from two to six with a median of four. Results: The median duration of follow-up was 72 months. The 5-year overall survival rate (OS) was 30.5% in the POCRT group, and 14.4% in the POCT group (p = 0.007). The 5-year disease-free survival rate (DFS) was 22.2% in POCRT group and 9.3% in POCT group (p = 0.003). In a multivariate analysis, N1 nodal involvement (N1+/N2+) was associated with significantly worse OS (HR = 1.454, 95% CI, 1.012-2.087, p = 0.043) and DFS (HR = 1.685, 95% CI, 1.196-2.372, p = 0.003). Absence of radiotherapy and treatment with fewer than three cycles of chemotherapy both were poor prognostic factors for both OS and DFS. Conclusions: As compared with chemotherapy alone, adjuvant treatment with both radiotherapy and chemotherapy improves survival in patients with completely resected Stage III-N2 nodal disease in NSCLC. Future study of treatment modality with radiotherapy and chemotherapy is warranted, especially focusing on both N1 and N2 nodal status. © 2010 Elsevier Inc. All rights reserved. Source

Discover hidden collaborations